Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 14;10(1):1936392. doi: 10.1080/2162402X.2021.1936392

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Lower KIR ligand numbers and peripheral blood KIR⁻ NK cell frequency are good prognostic markers of rituximab responses in lymphoma patients. (a) Pie charts representing the distribution of lymphoma patients (n = 74) following clinical outcome (CR, PR, and SD/PD) and CD16 polymorphism (VV, VF, and FF). (b) Pie charts representing the distribution of lymphoma patients following clinical outcome (CR, PR, and SD/PD) and the number of KIR ligands (2, 3, 4 or ≥5). (c) Pie charts representing the distribution of lymphoma patients following clinical outcome (CR, PR, and SD/PD) and the KIR⁻ NK cell frequency (≤ 44.5, 44.5–56.80, 56.80–71.80 and ≥ 71.80). (d) KIR⁺ NK cell frequencies following the number of KIR ligands for all lymphoma patients. The green and blue lines determine the significant difference between 2 groups for CR and SD/PD outcomes *p < .05